EUVIMEDEUVIMED entdecken
Crossref

Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation

Caterina Gregorio iD, Marta Spreafico iD, Saverio D'Amico iD, Elisabetta Sauta iD, Gianluca Asti iD, Luca Lanino iD, Cristina Astrid Tentori, Uwe Platzbecker iD, Torsten Haferlach, Maria Diez-Campelo iD, Pierre Fenaux, Rami Komrokji iD und 2 weitere

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.23.00205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Caterina Gregorio und 13 weiteren Autor:innen. Beteiligte Einrichtung: MOX-Modelling and Scientific Computing Laboratory, Politecnico di Milano, Department of Mathematics, Milan, Italy. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Transplantation, Homologous, Precision Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Decision about the optimal timing of a treatment procedure in patients with hematologic neoplasms is critical, especially for cellular therapies (most including allogeneic hematopoietic stem-cell transplantation [HSCT]). In the absence of evidence from randomized trials, real-world observational data become beneficial to study the effect of the treatment timing. In this study, a framework to estimate the expected outcome after an intervention in a time-to-event scenario is developed, with the aim of optimizing the timing in a personalized manner. METHODS Retrospective real-world data are leveraged to emulate a target trial for treatment timing using multistate modeling and microsimulation. This case study focuses on myelodysplastic syndromes, serving as a prototype for rare cancers characterized by a heterogeneous clinical course and complex genomic background. A cohort of 7,118 patients treated according to conventional available treatments/evidence across Europe and United States is analyzed. The primary clinical objective is to determine the ideal timing for HSCT, the only curative option for these patients. RESULTS This analysis enabled us to identify the most appropriate time frames for HSCT on the basis of each patient's unique profile, defined by a combination relevant patients' characteristics. CONCLUSION The developed methodology offers a structured framework to address a relevant clinical issue in the field of hematology. It makes several valuable contributions: (1) novel insights into how to develop decision models to identify the most favorable HSCT timing, (2) evidence to inform clinical decisions in a real-world context, and (3) the incorporation of complex information into decision making. This framework can be applied to provide medical insights for clinical issues that cannot be adequately addressed through randomized clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHematologic NeoplasmsTransplantation, HomologousPrecision MedicineHumansMaleMiddle AgedFemaleAdultAgedRetrospective StudiesMyelodysplastic SyndromesYoung Adult

Autor:innen und Institutionen

  • MOX-Modelling and Scientific Computing Laboratory, Politecnico di Milano, Department of Mathematics, Milan, Italy.
  • Biostatistics Unit, Department of Medical Sciences, University of Trieste, Trieste, Italy.
  • Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
  • Mathematical Institute, Leiden University, Leiden, the Netherlands.
  • Humanitas Clinical and Research Center-IRCCS, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.

ORCID-Profile: Caterina Gregorio, Marta Spreafico, Saverio D'Amico, Elisabetta Sauta, Gianluca Asti, Luca Lanino, Uwe Platzbecker, Maria Diez-Campelo, Rami Komrokji, Matteo Giovanni Della Porta

Zitieren

APA

Gregorio, C., Spreafico, M., D'Amico, S., Sauta, E., Asti, G., Lanino, L., Tentori, C. A., Platzbecker, U., Haferlach, T., Diez-Campelo, M., Fenaux, P., Komrokji, R., Della Porta, M. G., & Ieva, F. (2024). Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.23.00205

Vancouver

Gregorio C, Spreafico M, D'Amico S, Sauta E, Asti G, Lanino L, et al. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.23.00205

BibTeX
@article{Gregorio2024,
  author = {Gregorio, Caterina and Spreafico, Marta and D'Amico, Saverio and Sauta, Elisabetta and Asti, Gianluca and Lanino, Luca and Tentori, Cristina Astrid and Platzbecker, Uwe and Haferlach, Torsten and Diez-Campelo, Maria and Fenaux, Pierre and Komrokji, Rami and Della Porta, Matteo Giovanni and Ieva, Francesca},
  title = {Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.23.00205}
}
Kostenlos starten →